JAK2 Inhibitor Testing in Jak2 V617F Mouse Models: Comprehensive Preclinical Evaluation Services

The Jak2 V617F mutation drives the pathogenesis of myeloproliferative neoplasms (MPNs), making the Jak2 V617F knock-in mouse model the gold standard for evaluating JAK2 inhibitor efficacy in vivo. Our comprehensive JAK2 inhibitor testing platform combines pharmacokinetic profiling, pharmacodynamic biomarker analysis, and hematological assessment to accelerate your preclinical oncology and hematology programs. From ruxolitinib to next-generation selective inhibitors, we deliver reproducible, GLP-compliant data to support your IND-enabling studies.

Technical Overview

The Janus kinase 2 (JAK2) V617F mutation is a somatic gain-of-function substitution occurring within the pseudokinase domain (JH2) of the JAK2 protein, present in approximately 95% of polycythemia vera patients and 50–60% of patients with essential thrombocythemia and primary myelofibrosis. This mutation disrupts the autoinhibitory function of the JH2 domain, leading to constitutive activation of the JAK2-STAT signaling pathway, uncontrolled myeloproliferation, and systemic inflammatory responses. The Jak2 V617F conditional knock-in mouse model, in which the human V617F mutation is inserted into the endogenous murine Jak2 locus, faithfully recapitulates the human disease phenotype, including polycythemia, splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, and elevated proinflammatory cytokines. This model has become the industry-standard in vivo platform for testing JAK2 inhibitors such as ruxolitinib, fedratinib, pacritinib, momelotinib, and emerging selective type-II and allosteric JAK2 inhibitors.

JAK2 inhibitor testing in the Jak2 V617F mouse model evaluates drug candidate performance across multiple dimensions: pharmacokinetic exposure, target engagement, pharmacodynamic pathway suppression, disease-modifying efficacy, and safety tolerability. Because JAK2 is essential for normal erythropoiesis and thrombopoiesis, therapeutic window assessment—particularly regarding anemia and thrombocytopenia—is a critical component of the testing paradigm. A well-designed in vivo study integrates hematological endpoints, splenomegaly reduction, phospho-STAT biomarker modulation, and cytokine suppression to build a complete translational efficacy profile.

Testing Samples

Peripheral Blood and Plasma

Serial blood sampling (submandibular or retro-orbital collection) provides material for complete blood counts (CBC), plasma drug concentration determination via LC-MS/MS, and circulating cytokine quantification. Blood volume is carefully managed according to IACUC guidelines, typically limiting single draws to 10% of total circulating volume.

Bone Marrow Cells

Femoral and tibial bone marrow is harvested for flow cytometric analysis of hematopoietic stem and progenitor cell (HSPC) populations, colony-forming unit (CFU) assays, and intracellular phospho-STAT5/STAT3 staining to quantify residual malignant signaling in the target compartment.

Spleen and Liver Tissues

Splenic and hepatic tissues are collected at necropsy for organ weight measurement (splenomegaly index), histopathological assessment of extramedullary hematopoiesis, reticulin fibrosis scoring, Western blot analysis of JAK-STAT pathway proteins, and quantitative PCR of inflammatory gene transcripts.

Serum and Tissue Homogenates

Serum samples support ELISA-based cytokine panels (IL-6, TNF-α, IL-1β, G-CSF), while tissue homogenates from spleen and marrow enable simultaneous measurement of drug exposure and downstream biomarker suppression at the pharmacological site of action.

Testing Items

Our JAK2 inhibitor testing panel encompasses the following core evaluation categories:

• Pharmacokinetics (PK): plasma concentration–time profiles, Cmax, Tmax, AUC, half-life, oral bioavailability, and dose proportionality following single-dose and repeat-dose administration.
• Pharmacodynamics (PD): inhibition of phospho-STAT5, phospho-STAT3, and phospho-ERK in whole blood, bone marrow, and splenocytes measured by phospho-flow cytometry, Western blot, or MSD electrochemiluminescence assays.
• Hematological efficacy: normalization of elevated hematocrit, hemoglobin, red blood cell counts, white blood cell counts, and platelet counts; monitoring of treatment-emergent anemia and thrombocytopenia.
• Splenomegaly assessment: spleen weight-to-body weight ratio, spleen length measurement by ultrasound imaging, and histological quantification of extramedullary hematopoiesis.
• Survival analysis: Kaplan–Meier survival curves demonstrating extension of median and maximal survival in diseased mice.
• Inflammatory cytokine suppression: multiplex measurement of MPN-associated cytokines including IL-6, TNF-α, MCP-1, and G-CSF.
• BM fibrosis grading: reticulin and collagen staining with semi-quantitative scoring according to established myelofibrosis grading scales.
• Toxicology and tolerability: body weight tracking, clinical observations, serum chemistry (ALT, AST, creatinine), and gross necropsy findings.

Testing Methods

Testing is performed using validated, platform-appropriate methodologies under standardized operating procedures:

• Hematology analysis: automated veterinary hematology analyzers calibrated for murine samples, with manual smear review for morphological abnormalities and reticulocyte counting.
• Bioanalysis (LC-MS/MS): validated liquid chromatography–tandem mass spectrometry assays with matrix-matched calibration curves, achieving LLOQs in the low ng/mL range for plasma and tissue matrices.
• Phospho-flow cytometry: ex vivo stimulation with cytokines (EPO, TPO, IL-3, IFN-α) followed by intracellular phospho-STAT staining, enabling pathway-specific target engagement assessment in defined cell subsets.
• Western blot and capillary immunoassay (Wes/ Jess): quantitative detection of total and phosphorylated JAK2, STAT5, STAT3, and downstream effectors from tissue lysates.
• qRT-PCR and RNA sequencing: transcriptional profiling of JAK-STAT target genes and inflammatory signatures in sorted HSPC populations and whole tissues.
• Colony-forming assays: methylcellulose-based CFU-GM and BFU-E cultures assessing selective suppression of V617F-mutant versus normal progenitor outgrowth.
• Histopathology and immunohistochemistry: H&E staining, reticulin silver stain, and IHC markers (CD71, Ter119, Ly6G, F4/80) evaluated by board-certified veterinary pathologists.
• Flow cytometry immunophenotyping: multi-color panels delineating LSK cells, myeloid progenitors, mature lineage compartments, and mutant allele burden enrichment by genotyping.

Applications

JAK2 inhibitor testing in the Jak2 V617F mouse model supports a wide range of preclinical development objectives:

• Efficacy benchmarking of novel JAK2 inhibitors against clinically approved standards of care such as ruxolitinib and fedratinib.
• PK/PD modeling to establish exposure–response relationships and define the minimum efficacious concentration required for sustained STAT pathway inhibition.
• Dose selection and schedule optimization (once-daily versus twice-daily dosing, continuous versus intermittent regimens) for IND-enabling toxicology studies.
• Therapeutic window characterization, particularly separation between myeloproliferation control and on-target hematologic toxicity such as anemia.
• Evaluation of combination strategies, including JAK2 inhibitors paired with PI3K inhibitors, BCL-xL inhibitors, BET inhibitors, hypomethylating agents, or interferon.
• Assessment of disease modification beyond symptom control, including reversal of bone marrow fibrosis and reduction of mutant allele burden.
• Support for myelofibrosis, polycythemia vera, and essential thrombocythemia indication expansion programs.
• Translational biomarker discovery and qualification for patient stratification in subsequent clinical trials.

FAQ

What is the typical study duration for JAK2 inhibitor testing in Jak2 V617F mice?

A standard efficacy study runs 4 to 8 weeks of dosing, with disease onset and baseline characterization performed 2 to 4 weeks prior to treatment initiation depending on the model variant. Survival studies may extend to 20 weeks or longer. Shorter 1 to 2-week pilot studies are frequently conducted first to confirm PK exposure and acute PD biomarker suppression before committing to full efficacy trials.

Which JAK2 inhibitors have been validated as positive controls in this model?

Ruxolitinib (JAK1/JAK2 inhibitor) is the most widely used benchmark compound, with published and internal data demonstrating spleen reduction, cytokine normalization, and symptom improvement. Fedratinib, pacritinib, and momelotinib have also been extensively characterized. We routinely include an approved comparator arm to contextualize the performance of client test articles.

Can you distinguish true disease modification from palliative pathway inhibition?

Yes. By combining long-term treatment with mutant allele burden quantification (allele-specific PCR or NGS), bone marrow fibrosis scoring, and progenitor colony assays, we can determine whether a compound reduces the malignant clone and reverses stromal pathology or merely suppresses downstream inflammatory signaling, as is characteristic of first-generation inhibitors.

How is the hematologic toxicity risk of JAK2 inhibition monitored?

CBC monitoring is performed weekly or biweekly throughout dosing, with focused attention on hemoglobin, reticulocytes, and platelet counts. Anemia and thrombocytopenia are the principal dose-limiting toxicities of JAK2 inhibition; integrated PK/PD/efficacy modeling is used to identify dosing windows that maintain efficacy while preserving normal hematopoiesis.

What sample sizes and statistical approaches are used?

Typical treatment groups comprise 8 to 12 mice per arm, powered to detect 20–30% differences in spleen weight and hematological parameters with 80% power at α = 0.05. Analyses employ ANOVA with appropriate post-hoc tests for multi-group comparisons, repeated-measures models for longitudinal CBC data, and log-rank testing for survival endpoints.

Do you offer both wild-type and disease control arms?

Yes. Every study includes age-matched wild-type controls, vehicle-treated Jak2 V617F disease controls, and typically a positive comparator inhibitor arm. This design enables calculation of percent normalization relative to healthy baseline, which is the most interpretable efficacy metric in this model.